12Nov/13

Gilead Sciences, Inc. (GILD): Gilead Five-year Revenue Outlook, Part 1 – Seeking Alpha

Gilead Sciences, Inc. (GILD): Gilead Five-year Revenue Outlook, Part 1
Seeking Alpha
submitted a NDA to the FDA for marketing approval to support the use of Idelalisib, for the treatment of indolent non-Hodgkin’s lymphoma for patients with refractory iNHL (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy.

and more »